Literature DB >> 32168484

Impact of cortical hemodynamic failure on both subsequent hemorrhagic stroke and effect of bypass surgery in hemorrhagic moyamoya disease: a supplementary analysis of the Japan Adult Moyamoya Trial.

Jun C Takahashi1, Takeshi Funaki2, Kiyohiro Houkin3, Satoshi Kuroda4, Miki Fujimura5, Yasutake Tomata6, Susumu Miyamoto2.   

Abstract

OBJECTIVE: Here, the authors aimed to determine whether the presence of cerebral hemodynamic failure predicts subsequent bleeding attacks and how it correlates with the effect of direct bypass surgery in hemorrhagic moyamoya disease.
METHODS: Data from the Japanese Adult Moyamoya (JAM) Trial were used in this study: 158 hemispheres in 79 patients. A newly formed expert panel evaluated the SPECT results submitted at trial enrollment and classified the cortical hemodynamic state of the middle cerebral artery territory of each hemisphere into one of the following three groups: SPECT stage (SS) 0 as normal, SS1 as decreased cerebrovascular reserve (CVR), and SS2 as decreased CVR with decreased baseline blood flow. In the nonsurgical cohort of the JAM Trial, the subsequent hemorrhage rate during the 5-year follow-up was compared between the SS0 (hemodynamic failure negative) and SS1+2 (hemodynamic failure positive) groups. The effect of direct or combined direct/indirect bypass surgery on hemorrhage prevention was examined in each subgroup.
RESULTS: The hemodynamic grade was SS0 in 59 (37.3%) hemispheres, SS1 in 87 (55.1%), and SS2 in 12 (7.6%). In the nonsurgical cohort, subsequent hemorrhage rates in the SS0 and SS1+2 groups were 12 cases per 1000 person-years and 67 cases per 1000 person-years, respectively. Kaplan-Meier analysis revealed that hemorrhagic events were significantly more common in the SS1+2 group (p = 0.019, log-rank test). Cox regression analysis showed that hemodynamic failure was an independent risk factor for subsequent hemorrhage (HR 5.37, 95% CI 1.07-27.02). In the SS1+2 subgroup, bypass surgery significantly suppressed hemorrhagic events during 5 years (p = 0.001, HR 0.16, 95% CI 0.04-0.57), with no significant effect in the SS0 group (p = 0.655, HR 1.56, 95% CI 0.22-11.10). Examination of effect modification revealed that the effect of surgery tended to differ nonsignificantly between these two subgroups (p = 0.056).
CONCLUSIONS: Hemodynamic failure is an independent risk factor for subsequent hemorrhage in hemorrhagic moyamoya disease. Direct bypass surgery showed a significant preventive effect in the hemodynamically impaired hemispheres. Thus, hemodynamic failure, as well as previously proposed factors such as choroidal anastomosis, should be considered for the surgical indication in hemorrhagic moyamoya disease.Clinical trial registration no.: C000000166 (umin.ac.jp).

Entities:  

Keywords:  bypass surgery; hemodynamic failure; hemorrhagic moyamoya disease; periventricular anastomosis; subsequent bleeding; vascular disorders

Mesh:

Year:  2020        PMID: 32168484     DOI: 10.3171/2020.1.JNS192392

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

1.  RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses.

Authors:  Liyin Zhang; Sherif Rashad; Yuan Zhou; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Cereb Blood Flow Metab       Date:  2022-06-25       Impact factor: 6.960

2.  Imaging features of adult moyamoya disease patients with anterior intracerebral hemorrhage based on high-resolution magnetic resonance imaging.

Authors:  Jiali Xu; Gary B Rajah; Houdi Zhang; Cong Han; Xuxuan Shen; Bin Li; Zhengxing Zou; Wenbo Zhao; Changhong Ren; Guiyou Liu; Yuchuan Ding; Qi Yang; Sijie Li; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2022-06-29       Impact factor: 6.960

3.  Larger Posterior Revascularization Associated with Reduction of Choroidal Anastomosis in Moyamoya Disease: A Quantitative Angiographic Analysis.

Authors:  T Funaki; A Miyakoshi; H Kataoka; J C Takahashi; Y Takagi; K Yoshida; T Kikuchi; Y Mineharu; M Okawa; Y Yamao; Y Fushimi; S Miyamoto
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-25       Impact factor: 4.966

4.  Cerebral Aneurysms with Internal Carotid Artery Agenesis: A Unique Case Similar to Moyamoya Disease and Literature Review.

Authors:  Soichiro Takamiya; Tetsuyuki Yoshimoto; Katsuhiko Maruichi
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-04-15       Impact factor: 1.742

5.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.

Authors:  Miki Fujimura; Teiji Tominaga; Satoshi Kuroda; Jun C Takahashi; Hidenori Endo; Kuniaki Ogasawara; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

6.  Recurrent hemorrhage risk associated with medial target medullary artery anastomosis from the periventricular collateral vessel in adult patients with moyamoya disease.

Authors:  Jian Wang; Liming Tang; Yongbo Yang; Qingrong Zhang; Xia Lu; Qun Liang; Yi Wang; Yichao Zhu; Shijie Na; Fang Liu
Journal:  BMC Neurol       Date:  2021-03-06       Impact factor: 2.474

7.  Daily Remote Ischemic Conditioning Can Improve Cerebral Perfusion and Slow Arterial Progression of Adult Moyamoya Disease-A Randomized Controlled Study.

Authors:  Jiali Xu; Qian Zhang; Gary B Rajah; Wenbo Zhao; Fang Wu; Yuchuan Ding; Bowei Zhang; Wenting Guo; Qi Yang; Xiurong Xing; Sijie Li; Xunming Ji
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

8.  Characterizing the neurocognitive profiles of children with moyamoya disease using the Das Naglieri cognitive assessment system.

Authors:  Yusuke Kusano; Takeshi Funaki; Keita Ueda; Noyuri Nishida; Kanade Tanaka; Susumu Miyamoto; Shuichi Matsuda
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

Review 9.  A critical appraisal of bypass surgery in moyamoya disease.

Authors:  Michael Moussouttas; Igor Rybinnik
Journal:  Ther Adv Neurol Disord       Date:  2020-05-26       Impact factor: 6.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.